<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528112</url>
  </required_header>
  <id_info>
    <org_study_id>91665</org_study_id>
    <secondary_id>310442</secondary_id>
    <secondary_id>G04209F</secondary_id>
    <secondary_id>G04209G</secondary_id>
    <secondary_id>2007-000420-40</secondary_id>
    <nct_id>NCT00528112</nct_id>
  </id_info>
  <brief_title>Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study</brief_title>
  <official_title>Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS).
      The purpose of the study is to investigate which of the 2 administered doses is the lowest
      effective intrauterine dose of Levonorgestrel (LNG) administered via the LCS for
      contraception during 3 years. The study was amended: the LCS16 arm will be extended up to 5
      years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drop out-rate will be covered in Participant flow section.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pearl Index up to 3 Years</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The unadjusted Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 3-year PI was obtained by dividing the number of pregnancies that occurred during the first three years of treatment by the time (in 100 women years) that the women were at risk of getting pregnant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pearl Index for LCS16 up to 5 Years</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The unadjusted Pearl Index (PI) is defined as the number of pregnancies per 100 woman years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 1</measure>
    <time_frame>Day 1 to Day 90</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 2</measure>
    <time_frame>Day 91 to Day 180</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 3</measure>
    <time_frame>Day 181 to Day 270</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 4</measure>
    <time_frame>Day 271 to Day 360</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 12</measure>
    <time_frame>Day 991 to Day 1080</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 1</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 2</measure>
    <time_frame>Day 31 to Day 60</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 3</measure>
    <time_frame>Day 61 to Day 90</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 4</measure>
    <time_frame>Day 91 to Day 120</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 12</measure>
    <time_frame>Day 331 to Day 360</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With/Without Ovulation - Year 1</measure>
    <time_frame>For six weeks in the second half of Year 1</time_frame>
    <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With/Without Ovulation - Year 2</measure>
    <time_frame>For six weeks in the second half of Year 2</time_frame>
    <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With/Without Ovulation - Year 3</measure>
    <time_frame>For six weeks in the second half of Year 3</time_frame>
    <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Total Cervical Score - Year 1</measure>
    <time_frame>For six weeks in the second half of Year 1</time_frame>
    <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus. Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Total Cervical Score - Year 2</measure>
    <time_frame>For six weeks in the second half of Year 2</time_frame>
    <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus.
Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Total Cervical Score - Year 3</measure>
    <time_frame>For six weeks in the second half of Year 3</time_frame>
    <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus. Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification of Endometrium - Year 1</measure>
    <time_frame>At Year 1</time_frame>
    <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification of Endometrium - Year 2</measure>
    <time_frame>At Year 2</time_frame>
    <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification of Endometrium - Year 3 / End of Study</measure>
    <time_frame>At Year 3 / End of study</time_frame>
    <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of User Overall Satisfaction With Study Treatment</measure>
    <time_frame>At the end of study/Year 3</time_frame>
    <description>Overall user satisfaction was assessed by a questionnaire given to participants at the end of the study. The questionnaire was only given to participants whose end-of-study visit occurred after implementation of Protocol Amendment 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Partial or Total Expulsion</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>If LCS was displaced, but still in the cervical canal, it was assessed as being partially displaced. If LCS was expelled from the uterus, it was assessed as a total expulsion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 13</measure>
    <time_frame>Day 1081 to Day 1170</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 20</measure>
    <time_frame>Day 1711 to Day 1800</time_frame>
    <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of User Overall Satisfaction With Study Treatment up to 5 Years</measure>
    <time_frame>At the end of study/Year 5</time_frame>
    <description>Overall user satisfaction was assessed by a questionnaire given to participants at the end of the study. The questionnaire was only given to participants whose end-of-study visit occurred after implementation of Protocol Amendment 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Partial or Total Expulsion up to 5 Years</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>If LCS was displaced, but still in the cervical canal, it was assessed as being partially displaced. If LCS was expelled from the uterus, it was assessed as a total expulsion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2885</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>LCS12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCS16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCS12</intervention_name>
    <description>Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h</description>
    <arm_group_label>LCS12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCS16</intervention_name>
    <description>Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h</description>
    <arm_group_label>LCS16</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 35 years (inclusive), in good general health and requesting
             contraception.

          -  Has regular menstrual cycles (length of cycle 21-35 days) (i.e., endogenous cyclicity
             without hormonal contraceptive use).

        Exclusion Criteria:

          -  Known or suspected pregnancy or is lactating.

          -  History of ectopic pregnancies.

          -  Any genital infection (until successfully treated).

          -  Abnormal uterine bleeding of unknown origin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pacific Palisades</city>
        <state>California</state>
        <zip>90272</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boyton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moorestown</city>
        <state>New Jersey</state>
        <zip>08057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903-2685</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lanus Oeste</city>
        <state>Buenos Aires</state>
        <zip>1824</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Isidro</city>
        <state>Buenos Aires</state>
        <zip>B1642CLN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1425ASQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 6H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawinigan</city>
        <state>Quebec</state>
        <zip>G9N 2H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7H 5M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1S 2L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00260</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joensuu</city>
        <zip>80100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kotka</city>
        <zip>48100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuopio</city>
        <zip>70110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lahti</city>
        <zip>15110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>90570</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20540</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>COMPIEGNE cedex</city>
        <zip>60204</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quetigny</city>
        <zip>21800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>REIMS Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1116</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torreón</city>
        <state>Coahuila</state>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>México, D.F.</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hermosillo</city>
        <state>Sonora</state>
        <zip>83100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>México, D.F.</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>México, D.F.</city>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alkmaar</city>
        <zip>1817 MS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elverum</city>
        <zip>2403</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolbotn</city>
        <zip>1411</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larvik</city>
        <zip>3264</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0364</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7014</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>416 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luleå</city>
        <zip>972 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmö</city>
        <zip>217 44</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norrköping</city>
        <zip>602 22</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Russian Federation</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <results_reference>
    <citation>Nahum GG, Kaunitz AM, Rosen K, Schmelter T, Lynen R. Ovarian cysts: presence and persistence with use of a 13.5mg levonorgestrel-releasing intrauterine system. Contraception. 2015 May;91(5):412-7. doi: 10.1016/j.contraception.2015.01.021. Epub 2015 Feb 7.</citation>
    <PMID>25661510</PMID>
  </results_reference>
  <results_reference>
    <citation>Apter D, Gemzell-Danielsson K, Hauck B, Rosen K, Zurth C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014 Jun;101(6):1656-62.e1-4. doi: 10.1016/j.fertnstert.2014.03.004. Epub 2014 Apr 14.</citation>
    <PMID>24726226</PMID>
  </results_reference>
  <results_reference>
    <citation>Nelson A, Apter D, Hauck B, Schmelter T, Rybowski S, Rosen K, Gemzell-Danielsson K. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013 Dec;122(6):1205-13. doi: 10.1097/AOG.0000000000000019. Erratum in: Obstet Gynecol. 2014 May;123(5):1109.</citation>
    <PMID>24240244</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2007</study_first_submitted>
  <study_first_submitted_qc>September 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <results_first_submitted>July 11, 2012</results_first_submitted>
  <results_first_submitted_qc>August 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2012</results_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Intrauterine</keyword>
  <keyword>IUD</keyword>
  <keyword>IUS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LCS12</title>
          <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro. Treatment up to 3 years.</description>
        </group>
        <group group_id="P2">
          <title>LCS16</title>
          <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro. Treatment up to 5 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment up to 3 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1432"/>
                <participants group_id="P2" count="1453"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1432">Full analysis set/Safety population</participants>
                <participants group_id="P2" count="1452">Full analysis set/Safety population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="819"/>
                <participants group_id="P2" count="870"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="613"/>
                <participants group_id="P2" count="583"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="278"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="186"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Only subjects in the LCS16 groups could participate in the extension phase</participants>
                <participants group_id="P2" count="707"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="550"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCS12</title>
          <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
        </group>
        <group group_id="B2">
          <title>LCS16</title>
          <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1432"/>
            <count group_id="B2" value="1452"/>
            <count group_id="B3" value="2884"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" lower_limit="18" upper_limit="35"/>
                    <measurement group_id="B2" value="27.1" lower_limit="18" upper_limit="35"/>
                    <measurement group_id="B3" value="27.1" lower_limit="18" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤ 25 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="566"/>
                    <measurement group_id="B2" value="564"/>
                    <measurement group_id="B3" value="1130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 25 years ≤ 35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="866"/>
                    <measurement group_id="B2" value="888"/>
                    <measurement group_id="B3" value="1754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1432"/>
                    <measurement group_id="B2" value="1452"/>
                    <measurement group_id="B3" value="2884"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pearl Index up to 3 Years</title>
        <description>The unadjusted Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 3-year PI was obtained by dividing the number of pregnancies that occurred during the first three years of treatment by the time (in 100 women years) that the women were at risk of getting pregnant.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Pearl Index up to 3 Years</title>
          <description>The unadjusted Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 3-year PI was obtained by dividing the number of pregnancies that occurred during the first three years of treatment by the time (in 100 women years) that the women were at risk of getting pregnant.</description>
          <population>Full analysis set</population>
          <units>Pregnancies per 100 women years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1432"/>
                <count group_id="O2" value="1452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.16" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.15" upper_limit="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Cumulative failure rate (Kaplan-Meier) at 3 years</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>failure rate</param_type>
            <param_value>0.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.017</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cumulative failure rate (Kaplan-Meier) at 3 years</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>failure rate</param_type>
            <param_value>0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.018</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 1</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 1 to Day 90</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 1</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1322"/>
                <count group_id="O2" value="1348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="19.1"/>
                    <measurement group_id="O2" value="39.7" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="12.3"/>
                    <measurement group_id="O2" value="17.7" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="14.1"/>
                    <measurement group_id="O2" value="21.9" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 2</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 91 to Day 180</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 2</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1262"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="14.8"/>
                    <measurement group_id="O2" value="21.1" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="8.7"/>
                    <measurement group_id="O2" value="8.7" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="10.4"/>
                    <measurement group_id="O2" value="12.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 3</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 181 to Day 270</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 3</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1192"/>
                <count group_id="O2" value="1238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="13.2"/>
                    <measurement group_id="O2" value="16.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="8.2"/>
                    <measurement group_id="O2" value="6.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="9.0"/>
                    <measurement group_id="O2" value="10.0" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 4</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 271 to Day 360</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 4</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
                <count group_id="O2" value="1175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="12.1"/>
                    <measurement group_id="O2" value="14.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="7.2"/>
                    <measurement group_id="O2" value="5.1" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="8.3"/>
                    <measurement group_id="O2" value="9.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 12</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 991 to Day 1080</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 12</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="770"/>
                <count group_id="O2" value="819"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="9.9"/>
                    <measurement group_id="O2" value="10.2" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="5.9"/>
                    <measurement group_id="O2" value="3.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="7.1"/>
                    <measurement group_id="O2" value="6.9" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 1</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 1 to Day 30</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 1</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1355"/>
                <count group_id="O2" value="1376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="8.0"/>
                    <measurement group_id="O2" value="17.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="6.0"/>
                    <measurement group_id="O2" value="8.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="6.5"/>
                    <measurement group_id="O2" value="9.2" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 2</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 31 to Day 60</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 2</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1345"/>
                <count group_id="O2" value="1375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="7.6"/>
                    <measurement group_id="O2" value="12.9" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="4.9"/>
                    <measurement group_id="O2" value="5.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="5.9"/>
                    <measurement group_id="O2" value="7.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 3</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 61 to Day 90</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 3</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1328"/>
                <count group_id="O2" value="1355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="6.9"/>
                    <measurement group_id="O2" value="9.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="4.1"/>
                    <measurement group_id="O2" value="4.1" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="5.2"/>
                    <measurement group_id="O2" value="5.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 4</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 91 to Day 120</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 4</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1300"/>
                <count group_id="O2" value="1334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="6.0"/>
                    <measurement group_id="O2" value="7.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="3.6"/>
                    <measurement group_id="O2" value="3.2" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="4.5"/>
                    <measurement group_id="O2" value="4.6" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 12</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 331 to Day 360</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 30-day Reference Periods - Reference Period 12</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1130"/>
                <count group_id="O2" value="1186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="4.7"/>
                    <measurement group_id="O2" value="4.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.8"/>
                    <measurement group_id="O2" value="1.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.4"/>
                    <measurement group_id="O2" value="3.0" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With/Without Ovulation – Year 1</title>
        <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
        <time_frame>For six weeks in the second half of Year 1</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With/Without Ovulation – Year 1</title>
          <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
          <population>A subset of women from the full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With ovulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without ovulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With/Without Ovulation – Year 2</title>
        <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
        <time_frame>For six weeks in the second half of Year 2</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With/Without Ovulation – Year 2</title>
          <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
          <population>A subset of women from the full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With ovulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without ovulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With/Without Ovulation – Year 3</title>
        <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
        <time_frame>For six weeks in the second half of Year 3</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With/Without Ovulation – Year 3</title>
          <description>Serum concentrations of progesterone were analyzed. All subjects with progesterone values equal to or greater than 2.5 ng/ml were assessed as having an ovulation.</description>
          <population>A subset of women from the full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With ovulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without ovulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Total Cervical Score – Year 1</title>
        <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus. Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
        <time_frame>For six weeks in the second half of Year 1</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Average Total Cervical Score – Year 1</title>
          <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus. Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
          <population>A subset of women from the full analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.067" spread="1.291"/>
                    <measurement group_id="O2" value="3.127" spread="1.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Total Cervical Score – Year 2</title>
        <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus.
Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
        <time_frame>For six weeks in the second half of Year 2</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Average Total Cervical Score – Year 2</title>
          <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus.
Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
          <population>A subset of women from the full analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.358" spread="1.272"/>
                    <measurement group_id="O2" value="2.798" spread="1.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Total Cervical Score – Year 3</title>
        <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus. Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
        <time_frame>For six weeks in the second half of Year 3</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Average Total Cervical Score – Year 3</title>
          <description>Cervical mucus samples were analyzed to determine any effects of progesterone on the cervical mucus. Range of score: 0 (high contraceptive efficacy) to 12 (low contraceptive efficacy)</description>
          <population>A subset of women from the full analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.837" spread="1.354"/>
                    <measurement group_id="O2" value="2.448" spread="1.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Classification of Endometrium – Year 1</title>
        <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
        <time_frame>At Year 1</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Classification of Endometrium – Year 1</title>
          <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
          <population>A subset of women from the full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrophic/inactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secretory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Menstrual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Classification of Endometrium – Year 2</title>
        <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
        <time_frame>At Year 2</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Classification of Endometrium – Year 2</title>
          <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
          <population>A subset of women from the full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrophic/inactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secretory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Menstrual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Classification of Endometrium – Year 3 / End of Study</title>
        <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
        <time_frame>At Year 3 / End of study</time_frame>
        <population>A subset of women from the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Classification of Endometrium – Year 3 / End of Study</title>
          <description>The histological evaluation of the endometrium examined the effects of progesterone on the endometrium</description>
          <population>A subset of women from the full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrophic/inactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secretory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Menstrual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of User Overall Satisfaction With Study Treatment</title>
        <description>Overall user satisfaction was assessed by a questionnaire given to participants at the end of the study. The questionnaire was only given to participants whose end-of-study visit occurred after implementation of Protocol Amendment 3.</description>
        <time_frame>At the end of study/Year 3</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of User Overall Satisfaction With Study Treatment</title>
          <description>Overall user satisfaction was assessed by a questionnaire given to participants at the end of the study. The questionnaire was only given to participants whose end-of-study visit occurred after implementation of Protocol Amendment 3.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1053"/>
                <count group_id="O2" value="1063"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="796"/>
                    <measurement group_id="O2" value="842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither satisfied / dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Partial or Total Expulsion</title>
        <description>If LCS was displaced, but still in the cervical canal, it was assessed as being partially displaced. If LCS was expelled from the uterus, it was assessed as a total expulsion.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS12</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro</description>
          </group>
          <group group_id="O2">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Partial or Total Expulsion</title>
          <description>If LCS was displaced, but still in the cervical canal, it was assessed as being partially displaced. If LCS was expelled from the uterus, it was assessed as a total expulsion.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1426"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IUS partially expelled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IUS totally expelled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pearl Index for LCS16 up to 5 Years</title>
        <description>The unadjusted Pearl Index (PI) is defined as the number of pregnancies per 100 woman years.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Pearl Index for LCS16 up to 5 Years</title>
          <description>The unadjusted Pearl Index (PI) is defined as the number of pregnancies per 100 woman years.</description>
          <population>Full analysis set</population>
          <units>Pregnancies per 100 women years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.16" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Cumulative failure rate (Kaplan-Meier) at 5 years</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>failure rate</param_type>
            <param_value>0.01445</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00823</ci_lower_limit>
            <ci_upper_limit>0.02531</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 13</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 1081 to Day 1170</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 13</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="617"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 20</title>
        <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
        <time_frame>Day 1711 to Day 1800</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns in Days by 90-day Reference Periods - Reference Period 20</title>
          <description>The occurrence of genital bleeding was to be recorded by study subjects every day in a diary. Bleeding was to be recorded as light, normal or heavy, no bleeding, or spotting only. Spotting was defined as slight genital bleeding relative to the participant's experience.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="531"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bleeding/spotting days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of bleeding days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of spotting only days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of User Overall Satisfaction With Study Treatment up to 5 Years</title>
        <description>Overall user satisfaction was assessed by a questionnaire given to participants at the end of the study. The questionnaire was only given to participants whose end-of-study visit occurred after implementation of Protocol Amendment 3.</description>
        <time_frame>At the end of study/Year 5</time_frame>
        <population>All participants from the full analysis set who participated in the extension phase and had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of User Overall Satisfaction With Study Treatment up to 5 Years</title>
          <description>Overall user satisfaction was assessed by a questionnaire given to participants at the end of the study. The questionnaire was only given to participants whose end-of-study visit occurred after implementation of Protocol Amendment 3.</description>
          <population>All participants from the full analysis set who participated in the extension phase and had an assessment for this evaluation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither satisfied / dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Partial or Total Expulsion up to 5 Years</title>
        <description>If LCS was displaced, but still in the cervical canal, it was assessed as being partially displaced. If LCS was expelled from the uterus, it was assessed as a total expulsion.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>All participants from the full analysis set who had an assessment for this evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>LCS16</title>
            <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Partial or Total Expulsion up to 5 Years</title>
          <description>If LCS was displaced, but still in the cervical canal, it was assessed as being partially displaced. If LCS was expelled from the uterus, it was assessed as a total expulsion.</description>
          <population>All participants from the full analysis set who had an assessment for this evaluation</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IUS partially expelled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IUS totally expelled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of treatment until end of study, up to 5 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LCS12, up to 3 Years</title>
          <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro. Treatment up to 3 years.</description>
        </group>
        <group group_id="E2">
          <title>LCS16, up to 3 Years</title>
          <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro. Treatment up to 3 years.</description>
        </group>
        <group group_id="E3">
          <title>LCS16, up to 5 Years</title>
          <description>Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro. Treatment up to 5 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Spherocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Herpes dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Uterine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Loose body in joint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Axillary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Astrocytoma, low grade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Status migrainosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Panic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Polysubstance dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Strangury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Uterine spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Vaginal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Detoxification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="952" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="1014" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="1054" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="150" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="146" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="147" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="303" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="337" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="1452"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="1432"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="1452"/>
                <counts group_id="E3" subjects_affected="179" subjects_at_risk="1452"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal investigators (PIs) have to send the publication to sponsor 90 days prior to planned publishing. The sponsor has maximum 60 days for review and for recommending changes or mark parts that have to be deleted from the publication due to harming sponsor’s confidentiality rights. Sponsor can request a delay in publication release up to 6 months.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

